Fulgent Genetics (FLGT) Cash & Current Investments (2015 - 2026)

Fulgent Genetics has reported Cash & Current Investments for 12 years, with the latest figure at $257.0 million in Q2 2026.

• Quarterly Cash & Current Investments fell 12.25% year-over-year to $257.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $257.0 million (down 12.25% YoY) and the FY2025 annual result came in at $336.1 million, up 30.21% from the prior year.
• Cash & Current Investments declined to $257.0 million in Q2 2026 per FLGT's latest filing, from $276.3 million in the prior quarter.
• Over five years, Cash & Current Investments peaked at $585.1 million in Q1 2022 and troughed at $213.1 million in Q3 2024.
• A 5-year average of $388.9 million and a median of $355.9 million in 2025 frame the typical range for Cash & Current Investments.
• The sharpest annual moves came in 2024 and 2025: Cash & Current Investments plunged 54.45% in 2024, then soared 76.38% in 2025.
• Over 5 years, Cash & Current Investments stood at $526.2 million in 2022, then dropped by 19.4% to $424.2 million in 2023, then tumbled by 39.15% to $258.1 million in 2024, then jumped by 30.21% to $336.1 million in 2025, then declined by 23.52% to $257.0 million in 2026.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $257.0 million, $276.3 million, and $336.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.